Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of somavaratan in children with growth hormone deficiency
2016-002780-34Phase 3Terminated
- Sponsor
- Versartis, Inc.
- Start
- Sep 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somavaratan in growth hormone deficiency (GHD), sponsored by Versartis, Inc. Primary endpoint: Safety. Started Sep 2016; status: terminated.
02
Drugs
somavaratan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2016-002780-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002780-34.